Cephalon discontinues Nuvigil for schizophrenia
This article was originally published in Scrip
Executive Summary
Cephalon has discontinued the development of its Nuvigil (armodafinil) for the negative symptoms of schizophrenia after an interim analysis showed it had failed to meet the primary endpoint of a Phase II study.